{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:42:33Z","timestamp":1767339753469},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/ico.0b013e31821c9b44","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:01:48Z","timestamp":1317772908000},"page":"1213-1218","source":"Crossref","is-referenced-by-count":23,"title":["A Randomized Controlled Trial of Intralesional Bevacizumab Injection on Primary Pterygium: Preliminary Results"],"prefix":"10.1097","volume":"30","author":[{"given":"Orapin","family":"Enkvetchakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onsiri","family":"Thanathanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Rangsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaevalin","family":"Lekhanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olan","family":"Suwan-apichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210204","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1542-0124(12)70103-9","article-title":"The pathogenesis of pterygium: current concepts and their therapeutic implications.","volume":"6","author":"Chui","year":"2008","journal-title":"Ocul Surf"},{"key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1167\/iovs.06-1060","article-title":"Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium.","volume":"48","author":"Kato","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.eye.6702433","article-title":"Endothelial progenitor cells in pterygium pathogenesis.","volume":"21","author":"Lee","year":"2007","journal-title":"Eye (Lond)"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/IIO.0b013e3181924f62","article-title":"Pterygium: current concepts in pathogenesis and treatment.","volume":"49","author":"Todani","year":"2009","journal-title":"Int Ophthalmol Clin"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R6-6-20210204","first-page":"330","article-title":"Results of intra-operative 0.5mg\/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium.","volume":"46","author":"Mpyet","year":"2000","journal-title":"Cent Afr J Med"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/ICO.0b013e318162af90","article-title":"Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence.","volume":"27","author":"Paris Fdos","year":"2008","journal-title":"Cornea"},{"key":"R8-6-20210204","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2006.02.026","article-title":"Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.","volume":"113","author":"Prabhasawat","year":"2006","journal-title":"Ophthalmology"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1755-3768.1992.tb02127.x","article-title":"Excimer laser treatment of pterygium.","volume":"70","author":"Krag","year":"1992","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R10-6-20210204","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3928\/1542-8877-20000101-04","article-title":"Clinical application of Er:YAG laser for the treatment of pterygium.","volume":"31","author":"Nakamura","year":"2000","journal-title":"Ophthalmic Surg Lasers"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0886-3350(98)80223-X","article-title":"Excimer laser phototherapeutic keratectomy for recurrent pterygium.","volume":"24","author":"Talu","year":"1998","journal-title":"J Cataract Refract Surg"},{"key":"R12-6-20210204","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","article-title":"Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.","volume":"24","author":"Mauro","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"R13-6-20210204","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium.","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"R14-6-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R15-6-20210204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2008.155291","article-title":"Treatment of inflamed pterygia or residual pterygial bed.","volume":"93","author":"Mansour","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R16-6-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R17-6-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"R18-6-20210204","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","article-title":"Antiangiogenic therapy for pterygium recurrence [in German].","volume":"106","author":"Leippi","year":"2009","journal-title":"Ophthalmologe"},{"key":"R19-6-20210204","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.molmed.2010.01.004","article-title":"Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.","volume":"16","author":"Bagri","year":"2010","journal-title":"Trends Mol Med"},{"key":"R20-6-20210204","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14712590903208883","article-title":"VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.","volume":"9","author":"Greenberg","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R21-6-20210204","doi-asserted-by":"crossref","first-page":"516","DOI":"10.12968\/jowc.2009.18.12.45609","article-title":"A review of the current research on the role of bFGF and VEGF in angiogenesis.","volume":"18","author":"Przybylski","year":"2009","journal-title":"J Wound Care"},{"key":"R22-6-20210204","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1600-0463.2008.01138.x","article-title":"Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression.","volume":"116","author":"Kang","year":"2008","journal-title":"APMIS"},{"key":"R23-6-20210204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1684\/bdc.2010.1068","article-title":"Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab [in French].","volume":"97","author":"Barrascout","year":"2010","journal-title":"Bull Cancer"},{"key":"R24-6-20210204","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-2008-1027638","article-title":"Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV) [in German].","volume":"225","author":"Maier","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"R25-6-20210204","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/IAE.0b013e318198148e","article-title":"Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.","volume":"29","author":"Modarres","year":"2009","journal-title":"Retina"},{"key":"R26-6-20210204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-201111000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T23:59:53Z","timestamp":1639007993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201111000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31821c9b44","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}